KI 1120
Alternative Names: KI-1120Latest Information Update: 18 Apr 2022
At a glance
- Originator Kuhnil Pharmaceutical Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Decreased libido
Most Recent Events
- 05 Apr 2022 Preclinical trials in Decreased libido in South Korea (unspecified route) (Kuhnil Pharmaceutical Company pipeline, April 2022)